blinatumomab
astellas,amgen
['leusm', 'blinatumomab', 'fil,veral,12']
#ash22 #leusm boissel: mrd undetectable in 72% post-blin vs 53% in control cohort. allohct rate 47% vs 37%. 2.5yr dfs 72% vs 54%.os the same. subgroup analyses showed most benefit from blin in those mrd &lt;10e-4 pre-blin, interestingly. 
Assoc Professor, UCSF hematology/BMT. Translational researcher interested in leukemia, MDS, MRD, post-HCT relapse, GVHD, & immune recon. Photos: pyknosis (IG)